METASTATIC HEPATOCELLULAR CARCINOMA

This study tests whether giving a lower, less frequent dose of the cancer drug atezolizumab can still control tumors while causing fewer side effects. About 30 adults with advanced lung, liver, skin, or sarcoma cancers will receive the drug alone or with other treatments. Researc…

This early-stage study tests a new oral drug, TYRA-430, in people with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find a safe dose and check for side effects. About 100 adults will take part, and the st…

This study is for people with advanced liver cancer that cannot be removed by surgery and has gotten worse after initial treatment with atezolizumab plus bevacizumab. Researchers want to see if adding another immunotherapy drug (atezolizumab) to a standard targeted therapy pill (…

This early-phase study tests an experimental drug called ALN-BCAT, alone or with an immunotherapy (pembrolizumab), in people with advanced liver cancer that has spread. The drug targets a specific genetic change (WNT pathway mutation) found in some liver cancers. The main goals a…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific change in the β-catenin gene. The goal is to find the best dose and see if the combination can slow or stop tumor growth better than cabozantinib alone. Ab…

This early-phase study tests a new treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a specific marker called GPC3. The treatment is given after a short course of chemotherapy. The main goal is to see if this…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…

This study tests whether adding celecoxib (a pain reliever) to standard immunotherapy drugs (durvalumab and tremelimumab) can help control advanced liver cancer that has spread. About 39 adults with advanced or metastatic hepatocellular carcinoma will receive the combination. The…

This study tests a new medicine called PF-08634404, given alone or with another drug (ipilimumab), for adults with advanced liver cancer that cannot be removed by surgery. The goal is to check safety and see if the treatment shrinks tumors. About 138 participants will receive the…

This early-phase study tests a wearable device that creates low-intensity electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The go…

This study is for people with advanced gastrointestinal cancers that are spreading and no longer responding to immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system fight cancer throughout the body. About 28 participants will …

This early-stage study tests a new drug, BGB-B2033, alone or with other medicines, in people with advanced liver, stomach, lung, or yolk sac cancers that have spread. The main goals are to check safety and find the right dose. About 140 participants will take part.

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …